Jazz bet on Redx inhibitor program starts strong

June 15, 2022

Jazz Pharmaceuticals and partner Redx Pharma have announced that the U.S. FDA has cleared their IND application for an experimental pan-RAF inhibitor, launching clinical trials and triggering a $5M milestone payout to Redx.

The precision inhibitor, JZP815, is designed for the treatment of solid tumors and hematologic malignancies that contain mutations in the MAPK pathway. Ireland-based Jazz snatched up the asset in a 2019 deal with Redx, plunking down $3.5 million upfront with the promise of up to $203 million in additional milestone payments and royalties.

Promising preclinical data from the pan-RAF program was recently presented at the American Association for Cancer Research conference this past April. The therapy has a differentiated mechanism of action, and Jazz expects to assess its utility in treating several types of difficult-to-treat solid tumors where there remains significant unmet patient needs. 

Redx appears to be on a roll — JZP815 will be the fifth compound discovered by the UK biotech to enter the clinic. Jazz and Redx also have a separate collaboration agreement to discover and develop drug candidates in the RAS-RAF-MAP kinase (MAPK) pathway, where Redx is again responsible for research and preclinical development activities up to IND application to the FDA.